Abstract
The non-receptor tyrosine kinase Fyn-related kinase (FRK) is a member of the BRK family kinases (BFKs) and is distantly related to the Src family kinases (SFKs). FRK was first discovered in 1993, and studies pursued thereafter attributed a potential tumour-suppressive function to the enzyme. In recent years, however, further functional characterization of the tyrosine kinase in diverse cancer types suggests that FRK may potentially play an oncogenic role as well. Specifically, while ectopic expression of FRK suppresses cell proliferation and migration in breast and brain cancers, knockdown or catalytic inhibition of FRK suppresses these cellular processes in pancreatic and liver cancer. Such functional paradox is therefore evidently exhibited in a tissue-specific context. This review sheds light on the recent developments emerged from investigations on FRK which include: (a) a review of the expression pattern of the protein in mammalian cells/tissues, (b) underlying genomic perturbations and (c) a mechanistic function of the enzyme across different cellular environments. Given its functional heterogeneity observed across different cancers, we also discuss the therapeutic significance of FRK.
Similar content being viewed by others
References
Goel, R. K., & Lukong, K. E. (2015). Tracing the footprints of the breast cancer oncogene BRK—past till present. Biochimica et biophysica acta, 1856, 39–54.
Cance, W. G., Craven, R. J., Weiner, T. M., & Liu, E. T. (1993). Novel protein kinases expressed in human breast cancer, International journal of cancer. Journal international du cancer, 54, 571–577.
Cance, W. G., Craven, R. J., Bergman, M., Xu, L., Alitalo, K., & Liu, E. T. (1994). Rak, a novel nuclear tyrosine kinase expressed in epithelial cells. Cell growth & differentiation, 5, 1347–1355.
Lee, J., Wang, Z., Luoh, S. M., Wood, W. I., & Scadden, D. T. (1994). Cloning of FRK, a novel human intracellular SRC-like tyrosine kinase-encoding gene. Gene, 138, 247–251.
Brauer, P. M., & Tyner, A. L. (2009). RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. Cell Cycle, 8, 2728–2732.
Sheng, Z. M., Marchetti, A., Buttitta, F., Champeme, M. H., Campani, D., Bistocchi, M., Lidereau, R., & Callahan, R. (1996). Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. British journal of cancer, 73, 144–147.
Becher, R., Gibas, Z., Karakousis, C., & Sandberg, A. A. (1983). Nonrandom chromosome changes in malignant melanoma. Cancer research, 43, 5010–5016.
Becher, R., Gibas, Z., & Sandberg, A. A. (1983). Chromosome 6 in malignant melanoma. Cancer genetics and cytogenetics, 9, 173–175.
Girard, L., Zochbauer-Muller, S., Virmani, A. K., Gazdar, A. F., & Minna, J. D. (2000). Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer research, 60, 4894–4906.
Oberg-Welsh, C., & Welsh, M. (1995). Cloning of BSK, a murine FRK homologue with a specific pattern of tissue distribution. Gene, 152, 239–242.
Thuveson, M., Albrecht, D., Zurcher, G., Andres, A. C., & Ziemiecki, A. (1995). iyk, a novel intracellular protein tyrosine kinase differentially expressed in the mouse mammary gland and intestine. Biochemical and biophysical research communications, 209, 582–589.
Sunitha, I., & Avigan, M. I. (1994). A newly identified tyrosine kinase is preferentially expressed in the gastrointestinal tract. Biochimica et biophysica acta, 1221, 348–352.
Sunitha, I., & Avigan, M. I. (1996). The apical membranes of maturing gut columnar epithelial cells contain the enzymatically active form of a newly identified fyn-related tyrosine kinase. Oncogene, 13, 547–559.
Oberg-Welsh, C., Anneren, C., & Welsh, M. (1998). Mutation of C-terminal tyrosine residues Y497/Y504 of the Src-family member Bsk/Iyk decreases NIH3T3 cell proliferation. Growth Factors, 16, 111–124.
Anneren, C., & Welsh, M. (2000). Role of the Bsk/Iyk non-receptor tyrosine kinase for the control of growth and hormone production in RINm5F cells. Growth Factors, 17, 233–247.
Okada, M., & Nakagawa, H. (1989). A protein tyrosine kinase involved in regulation of pp60c-src function. The Journal of Biological Chemistry, 264, 20886–20893.
Nada, S., Okada, M., MacAuley, A., Cooper, J. A., & Nakagawa, H. (1991). Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature, 351, 69–72.
Partanen, J., Armstrong, E., Bergman, M., Makela, T. P., Hirvonen, H., Huebner, K., & Alitalo, K. (1991). cyl encodes a putative cytoplasmic tyrosine kinase lacking the conserved tyrosine autophosphorylation site (Y416src). Oncogene, 6, 2013–2018.
Sabe, H., Knudsen, B., Okada, M., Nada, S., Nakagawa, H., & Hanafusa, H. (1992). Molecular cloning and expression of chicken C-terminal Src kinase: lack of stable association with c-Src protein. Proceedings of the National Academy of Sciences of the United States of America, 89, 2190–2194.
Okada, M., Nada, S., Yamanashi, Y., Yamamoto, T., & Nakagawa, H. (1991). CSK: a protein-tyrosine kinase involved in regulation of src family kinases. The Journal of Biological Chemistry, 266, 24249–24252.
Meyer, T., Xu, L., Chang, J., Liu, E. T., Craven, R. J., & Cance, W. G. (2003). Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase, International journal of cancer. Journal international du cancer, 104, 139–146.
Qiu, H., & Miller, W. T. (2004). Role of the Brk SH3 domain in substrate recognition. Oncogene, 23, 2216–2223.
Snyder, M. A., Bishop, J. M., McGrath, J. P., & Levinson, A. D. (1985). A mutation at the ATP-binding site of pp60v-src abolishes kinase activity, transformation, and tumorigenicity. Molecular and cellular biology, 5, 1772–1779.
Goel, R. K., Miah, S., Black, K., Kalra, N., Dai, C., & Lukong, K. E. (2013). The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1. The FEBS journal, 280, 4539–4559.
McPherson, R. A., Taylor, M. M., Hershey, E. D., & Sturgill, T. W. (2000). A different function for a critical tryptophan in c-Raf and Hck. Oncogene, 19, 3616–3622.
Berclaz, G., Altermatt, H. J., Rohrbach, V., Dreher, E., Ziemiecki, A., & Andres, A. C. (2000). Hormone-dependent nuclear localization of the tyrosine kinase iyk in the normal human breast epithelium and loss of expression during carcinogenesis, International journal of cancer. Journal international du cancer, 85, 889–894.
Serfas, M. S., & Tyner, A. L. (2003). Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncology research, 13, 409–419.
L. Jin, R.J. Craven. (2013). The Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor. Oncogene.
Ie Kim, H., & Lee, S. T. (2009). Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus. Journal of biochemistry, 146, 133–139.
Brauer, P. M., Zheng, Y., Wang, L., & Tyner, A. L. (2010). Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells. Cell Cycle, 9, 4190–4199.
Peng, M., Emmadi, R., Wang, Z., Wiley, E. L., Gann, P. H., Khan, S. A., Banerji, N., McDonald, W., Asztalos, S., Pham, T. N., Tonetti, D. A., & Tyner, A. L. (2014). PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors. Oncotarget, 5, 6038–6048.
Zhou, X., Hua, L., Zhang, W., Zhu, M., Shi, Q., Li, F., Zhang, L., Song, C., & Yu, R. (2012). FRK controls migration and invasion of human glioma cells by regulating JNK/c-Jun signaling. Journal of neuro-oncology, 110, 9–19.
Hua, L., Zhu, M., Song, X., Wang, J., Fang, Z., Zhang, C., Shi, Q., Zhan, W., Wang, L., Meng, Q., Zhou, X., & Yu, R. (2014). FRK suppresses the proliferation of human glioma cells by inhibiting cyclin D1 nuclear accumulation. Journal of neuro-oncology, 119, 49–58.
Zhao, B., Tan, P. H., Li, S. S., & Pei, D. (2013). Systematic characterization of the specificity of the SH2 domains of cytoplasmic tyrosine kinases. Journal of proteomics, 81, 56–69.
Yim, E. K., Peng, G., Dai, H., Hu, R., Li, K., Lu, Y., Mills, G. B., Meric-Bernstam, F., Hennessy, B. T., Craven, R. J., & Lin, S. Y. (2009). Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell, 15, 304–314.
Craven, R. J., Cance, W. G., & Liu, E. T. (1995). The nuclear tyrosine kinase Rak associates with the retinoblastoma protein pRb. Cancer research, 55, 3969–3972.
Benedict, W. F., Murphree, A. L., Banerjee, A., Spina, C. A., Sparkes, M. C., & Sparkes, R. S. (1983). Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science, 219, 973–975.
Weinberg, R. A. (1995). The retinoblastoma protein and cell cycle control. Cell, 81, 323–330.
Welch, P. J., & Wang, J. Y. (1993). A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell, 75, 779–790.
Yim, E. K., Siwko, S., & Lin, S. Y. (2009). Exploring Rak tyrosine kinase function in breast cancer. Cell Cycle, 8, 2360–2364.
J.L. Kim, G.H. Ha, L. Campo, M.F. Denning, T.B. Patel, C. Osipo, S.Y. Lin, E.K. Breuer. (2015). The role of Rak in the regulation of stability and function of BRCA1. Oncotarget.
Yoshida, K., & Miki, Y. (2004). Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer science, 95, 866–871.
Bougie, O., & Weberpals, J. I. (2011). Clinical considerations of BRCA1- and BRCA2-mutation carriers: a review. International journal of surgical oncology, 2011, 374012.
Pendergast, A. M. (1996). Nuclear tyrosine kinases: from Abl to WEE1. Current opinion in cell biology, 8, 174–181.
Berthet, C., & Kaldis, P. (2006). Cdk2 and Cdk4 cooperatively control the expression of Cdc2. Cell division, 1, 10.
Anneren, C., Reedquist, K. A., Bos, J. L., & Welsh, M. (2000). GTK, a Src-related tyrosine kinase, induces nerve growth factor-independent neurite outgrowth in PC12 cells through activation of the Rap1 pathway. Relationship to Shb tyrosine phosphorylation and elevated levels of focal adhesion kinase. The Journal of Biological Chemistry, 275, 29153–29161.
Anneren, C., & Welsh, M. (2002). GTK tyrosine kinase-induced alteration of IRS-protein signalling in insulin producing cells. Molecular Medicine, 8, 705–713.
Anneren, C., Lindholm, C. K., Kriz, V., & Welsh, M. (2003). The FRK/RAK-SHB signaling cascade: a versatile signal-transduction pathway that regulates cell survival, differentiation and proliferation. Current molecular medicine, 3, 313–324.
Chen, J. S., Hung, W. S., Chan, H. H., Tsai, S. J., & Sun, H. S. (2013). In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma. Bioinformatics, 29, 420–427.
Je, D. W., YM, O., Ji, Y. G., Cho, Y., & Lee, D. H. (2014). The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion. Pancreas, 43, 768–776.
Tan, A. C., Jimeno, A., Lin, S. H., Wheelhouse, J., Chan, F., Solomon, A., Rajeshkumar, N. V., Rubio-Viqueira, B., & Hidalgo, M. (2009). Characterizing DNA methylation patterns in pancreatic cancer genome. Molecular oncology, 3, 425–438.
Klijn, C., Durinck, S., Stawiski, E. W., Haverty, P. M., Jiang, Z., Liu, H., Degenhardt, J., Mayba, O., Gnad, F., Liu, J., Pau, G., Reeder, J., Cao, Y., Mukhyala, K., Selvaraj, S. K., Yu, M., Zynda, G. J., Brauer, M. J., Wu, T. D., Gentleman, R. C., Manning, G., Yauch, R. L., Bourgon, R., Stokoe, D., Modrusan, Z., Neve, R. M., de Sauvage, F. J., Settleman, J., Seshagiri, S., & Zhang, Z. (2015). A comprehensive transcriptional portrait of human cancer cell lines. Nature biotechnology, 33, 306–312.
Hosoya, N., Qiao, Y., Hangaishi, A., Wang, L., Nannya, Y., Sanada, M., Kurokawa, M., Chiba, S., Hirai, H., & Ogawa, S. (2005). Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation. Genes, chromosomes & cancer, 42, 269–279.
Pilati, C., Letouze, E., Nault, J. C., Imbeaud, S., Boulai, A., Calderaro, J., Poussin, K., Franconi, A., Couchy, G., Morcrette, G., Mallet, M., Taouji, S., Balabaud, C., Terris, B., Canal, F., Paradis, V., Scoazec, J. Y., de Muret, A., Guettier, C., Bioulac-Sage, P., Chevet, E., Calvo, F., & Zucman-Rossi, J. (2014). Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell, 25, 428–441.
Knowlton, M. L., Selfors, L. M., Wrobel, C. N., Gu, T. L., Ballif, B. A., Gygi, S. P., Polakiewicz, R., & Brugge, J. S. (2010). Profiling Y561-dependent and -independent substrates of CSF-1R in epithelial cells. PloS one, 5, e13587.
Sunitha, I., Shen, R., McKillop, I. H., Lee, J. H., Resau, J., & Avigan, M. (1999). A src-related kinase in the brush border membranes of gastrointestinal cells is regulated by c-met. Experimental cell research, 250, 86–98.
Palka-Hamblin, H. L., Gierut, J. J., Bie, W., Brauer, P. M., Zheng, Y., Asara, J. M., & Tyner, A. L. (2010). Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6. Journal of Cell Science, 123, 236–245.
Shi, Q., Song, X., Wang, J., Gu, J., Zhang, W., Hu, J., Zhou, X., & Yu, R. (2015). FRK inhibits migration and invasion of human glioma cells by promoting N-cadherin/beta-catenin complex formation. Journal of molecular neuroscience, 55, 32–41.
Camand, E., Peglion, F., Osmani, N., Sanson, M., & Etienne-Manneville, S. (2012). N-cadherin expression level modulates integrin-mediated polarity and strongly impacts on the speed and directionality of glial cell migration. Journal of Cell Science, 125, 844–857.
Zhang, X., Liu, G., Kang, Y., Dong, Z., Qian, Q., & Ma, X. (2013). N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PloS one, 8, e57692.
Wang, J. L., Chen, Z. F., Chen, H. M., Wang, M. Y., Kong, X., Wang, Y. C., Sun, T. T., Hong, J., Zou, W., Xu, J., & Fang, J. Y. (2014). Elf3 drives beta-catenin transactivation and associates with poor prognosis in colorectal cancer. Cell death & disease, 5, e1263.
Kwon, Y. T., Gupta, A., Zhou, Y., Nikolic, M., & Tsai, L. H. (2000). Regulation of N-cadherin-mediated adhesion by the p35-Cdk5 kinase. Current biology, 10, 363–372.
Bhargava, R., Gerald, W. L., Li, A. R., Pan, Q., Lal, P., Ladanyi, M., & Chen, B. (2005). EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern pathology, 18, 1027–1033.
Rimawi, M. F., Shetty, P. B., Weiss, H. L., Schiff, R., Osborne, C. K., Chamness, G. C., & Elledge, R. M. (2010). Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer, 116, 1234–1242.
Sun, B., Yang, N., Jiang, Y., Zhang, H., Hou, C., Ji, C., Liu, Y., & Zuo, P. (2015). Antagomir-1290 suppresses CD133(+) cells in non-small cell lung cancer by targeting fyn-related Src family tyrosine kinase. Tumour biology, 36, 6223–6230.
Varnholt, H., Drebber, U., Schulze, F., Wedemeyer, I., Schirmacher, P., Dienes, H. P., & Odenthal, M. (2008). MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology, 47, 1223–1232.
Shukla, S., Shishodia, G., Mahata, S., Hedau, S., Pandey, A., Bhambhani, S., Batra, S., Basir, S. F., Das, B. C., & Bharti, A. C. (2010). Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Molecular cancer, 9, 282.
Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Kraker, A., & Jove, R. (2001). Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene, 20, 2499–2513.
Azare, J., Leslie, K., Al-Ahmadie, H., Gerald, W., Weinreb, P. H., Violette, S. M., & Bromberg, J. (2007). Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Molecular and cellular biology, 27, 4444–4453.
Welsh, M., Welsh, C., Ekman, M., Dixelius, J., Hagerkvist, R., Anneren, C., Akerblom, B., Mahboobi, S., Chandrasekharan, S., & Liu, E. T. (2004). The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity. The Biochemical journal, 382, 261–268.
Chandrasekharan, S., Qiu, T. H., Alkharouf, N., Brantley, K., Mitchell, J. B., & Liu, E. T. (2002). Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak. Molecular and cellular biology, 22, 5235–5247.
Akerblom, B., Anneren, C., & Welsh, M. (2007). A role of FRK in regulation of embryonal pancreatic beta cell formation. Molecular and cellular endocrinology, 270, 73–78.
Anneren, C., & Welsh, M. (2001). Increased cytokine-induced cytotoxicity of pancreatic islet cells from transgenic mice expressing the Src-like tyrosine kinase GTK. Molecular Medicine, 7, 301–310.
Anneren, C. (2002). Dual role of the tyrosine kinase GTK and the adaptor protein SHB in beta-cell growth: enhanced beta-cell replication after 60% pancreatectomy and increased sensitivity to streptozotocin. The Journal of endocrinology, 172, 145–153.
Anneren, C., Welsh, M., & Jansson, L. (2007). Glucose intolerance and reduced islet blood flow in transgenic mice expressing the FRK tyrosine kinase under the control of the rat insulin promoter, American journal of physiology. Endocrinology and metabolism, 292, E1183–1190.
Roe, K., Bratland, A., Vlatkovic, L., Ragnum, H. B., Saelen, M. G., Olsen, D. R., Marignol, L., & Ree, A. H. (2013). Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer. PloS one, 8, e63723.
Cowin, P. A., Anglesio, M., Etemadmoghadam, D., & Bowtell, D. D. (2010). Profiling the cancer genome. Annual review of genomics and human genetics, 11, 133–159.
Son, J. W., Jeong, K. J., Jean, W. S., Park, S. Y., Jheon, S., Cho, H. M., Park, C. G., Lee, H. Y., & Kang, J. (2011). Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients. Cancer letters, 311, 29–37.
Park, J. J., Kang, J. K., Hong, S., Ryu, E. S., Kim, J. I., Lee, J. H., & Seo, J. S. (2008). Genome-wide combination profiling of copy number and methylation offers an approach for deciphering misregulation and development in cancer cells. Gene, 407, 139–147.
Kleivi, K., Lothe, R. A., Heim, S., Tsarouha, H., Kraggerud, S. M., Pandis, N., Papadopoulou, A., Andersen, J., Jakobsen, K. S., & Teixeira, M. R. (2002). Genome profiling of breast cancer cells selected against in vitro shows copy number changes. Genes, chromosomes & cancer, 33, 304–309.
Kashiwagi, H., & Uchida, K. (2000). Genome-wide profiling of gene amplification and deletion in cancer. Human cell, 13, 135–141.
Chen, Y., Hao, J., Jiang, W., He, T., Zhang, X., Jiang, T., & Jiang, R. (2013). Identifying potential cancer driver genes by genomic data integration. Scientific reports, 3, 3538.
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009). The cancer genome. Nature, 458, 719–724.
Jin, G., Jeon, H. S., Yang, E., & Park, J. Y. (2011). Mutation analysis of the FRK gene in non-small cell lung cancers. Lung Cancer, 71, 115–117.
Grebien, F., Hantschel, O., Wojcik, J., Kaupe, I., Kovacic, B., Wyrzucki, A. M., Gish, G. D., Cerny-Reiterer, S., Koide, A., Beug, H., Pawson, T., Valent, P., Koide, S., & Superti-Furga, G. (2011). Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell, 147, 306–319.
Brauer, P. M., & Tyner, A. L. (2010). Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochimica et Biophysica Acta, 1806, 66–73.
Y. Zheng, J. Gierut, Z. Wang, J. Miao, J.M. Asara, A.L. Tyner. (2012). Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. Oncogene.
Zheng, Y., & Tyner, A. L. (2013). Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer. European journal of clinical investigation, 43, 397–404.
Haegebarth, A., Bie, W., Yang, R., Crawford, S. E., Vasioukhin, V., Fuchs, E., & Tyner, A. L. (2006). Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Molecular and cellular biology, 26, 4949–4957.
Ma, S., Bao, J. Y., Kwan, P. S., Chan, Y. P., Tong, C. M., Fu, L., Zhang, N., Tong, A. H., Qin, Y. R., Tsao, S. W., Chan, K. W., Lok, S., & Guan, X. Y. (2012). Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology, 143, 675–686. e671-612.
Liu, X. K., Zhang, X. R., Zhong, Q., Li, M. Z., Liu, Z. M., Lin, Z. R., Wu, D., & Zeng, M. S. (2013). Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma. Journal of translational medicine, 11, 59.
Li, X., Lu, Y., Liang, K., Hsu, J. M., Albarracin, C., Mills, G. B., Hung, M. C., & Fan, Z. (2012). Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene, 31, 4372–4383.
Xiang, B., Chatti, K., Qiu, H., Lakshmi, B., Krasnitz, A., Hicks, J., Yu, M., Miller, W. T., & Muthuswamy, S. K. (2008). Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 105, 12463–12468.
Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K. L., Gao, J., Song, L., Eschrich, S., Superti-Furga, G., Koomen, J., & Haura, E. B. (2010). A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nature chemical biology, 6, 291–299.
Montero, J. C., Seoane, S., Ocana, A., & Pandiella, A. (2011). Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clinical cancer research, 17, 5546–5552.
Acknowledgments
The authors apologize to those whose work was not included owing to space limitations. Breast cancer research in the Lukong lab is supported over the years by funds from various organizations including the Canadian Breast Cancer Foundation (CBCF) and Canadian Institutes of Health Research (CIHR).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors are unaware of any affiliations, memberships, or financial holdings that might be perceived as affecting the objectivity of this review.
Rights and permissions
About this article
Cite this article
Goel, R.K., Lukong, K.E. Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology. Cancer Metastasis Rev 35, 179–199 (2016). https://doi.org/10.1007/s10555-016-9623-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-016-9623-3